A major milestone for peptide therapeutics: the FDA has approved LIPFENDRA® (enlicitide), the first and only once-daily oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia. Merck and others are leading this exciting trend in macrocyclic peptides. This approval represents more than a new cholesterol therapy—it is an important milestone for the entire field. Macrocyclization offers significant advantages by improving peptide stability, target binding, and oral bioavailability. This approval clearly demonstrates its potential.
SHARE
